Skip to content
lifestyle.dietfitnessforall.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Annexon Biosciences
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
August 12, 2026
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
August 6, 2026
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 7, 2026
Annexon to Present at the Bank of America Securities Health Care Conference 2026
May 6, 2026
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 31, 2026
1
2
Next Page
→